|Bid||81.32 x 800|
|Ask||91.46 x 800|
|Day's Range||86.10 - 87.61|
|52 Week Range||71.50 - 95.72|
|Beta (5Y Monthly)||0.34|
|PE Ratio (TTM)||13.15|
|Earnings Date||Oct 27, 2022|
|Forward Dividend & Yield||2.76 (3.20%)|
|Ex-Dividend Date||Sep 14, 2022|
|1y Target Est||100.90|
Subscribe to Yahoo Finance Plus to view Fair Value for MRK
There wouldn't be many who think Merck & Co., Inc.'s ( NYSE:MRK ) price-to-earnings (or "P/E") ratio of 13.1x is worth...
In combination with Roche's (OTC: RHHBY) bevacizumab (Avastin), Merck's (NYSE: MRK) oncology medicine -- co-owned with AstraZeneca (NASDAQ: AZN) and known as Lynparza -- received the nod from China's National Medical Products Administration (NMPA) to treat patients with a form of advanced ovarian cancer. What led the NMPA to green-light the treatment combo?
RAHWAY, N.J., September 29, 2022--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, Inc. (now Viatris) related to sitagliptin dihydrogen phosphate, an active ingredient in JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin hydrochloride) and JANUMET® XR (sitagliptin and metformin hydrochloride extended-release